trial

The Staged Treatment in Early Psychosis Study

NCTId NCT02751632
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 342 (actual)
Sponsored by Orygen
Primary completion 2019-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
342 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2016-04
Primary completion
2019-07
Eligibility
ALL · 12 Years · 25 Years

Interventions & indications

Drugs
Support and Problem Solving TherapyCognitive Behavioural Case Managementfluoxetine3-monthly monitoring

Sponsors

OrygenLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
University of California Riverside at C.I. Trials, Inc.-Inland EmpireCollaborator

Investigators

1
Patrick McGorry, MD, PhDPrincipal Investigator

Sites

5 total
Craigieburn, AustraliaGlenroy, AustraliaMelbourne, AustraliaSunshine, AustraliaWerribee, Australia

Linked catalysts

1
The Staged Treatment in Early Psychosis Study — primary completion2019-07

Facts & assertions

4 sourced
Enrollment
342
Phase
PHASE3
Primary Completion Date
2019-07
Status
COMPLETED
relationships
The graph out of here
drug
Support and Problem Solving Therapy
drug
Cognitive Behavioural Case Management
drug
fluoxetine
drug
3-monthly monitoring
drug
lead_sponsor
Orygen
company
collaborator
National Institute of Mental Health (NIMH)
company
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Psychotic Disorders
indication
Personality Disorders
indication
Clinical High Risk
indication
investigator
Patrick McGorry, MD, PhD
person